MiMedx Q4 net sales $87M (+17% YoY); FY $321M (+20%); guides 2024 low double-digit growth

MIMEDX GROUP, INC.

2023-FY EPS reported $0.37 revenue$321,477,000

Net sales Q4 $87M, FY $321M, up 17% and 20% YoY respectively.
GAAP net income Q4 $53M (incl. $40M one-time tax benefit), FY $58M.
Adjusted EBITDA Q4 $21M, margin 24%.
2024 guidance: low double-digit net sales growth, adjusted EBITDA margin >20%.
Launched EPIEFFECT wound care product; completed debt refinancing Jan 2024.

item 2.02 item 7.01 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

MIMEDX GROUP, INC. reported the fourth quarter and full year ended December 31, 2023 results: revenue Fourth quarter and full year 2023 net sales of $87 million and $321 million, net income GAAP Net Income for the fourth quarter and full year 2023 of $53 million and $58 million, respectively.. Guidance reaffirmed.

Period: the fourth quarter and full year ended December 31, 2023
Revenue: Fourth quarter and full year 2023 net sales of $87 million and $321 million
Net income: GAAP Net Income for the fourth quarter and full year 2023 of $53 million and $58 million, respectively.
Guidance: reaffirmed
Result: reported results

Exact text from the filing

On February 28, 2024, MiMedx Group, Inc. (the “ Company ”), issued a press release (the “ Earnings Press Release ”) announcing its results for the fourth quarter and full year ended December 31, 2023.

View on SEC.gov

Browse all earnings releases →

MIMEDX GROUP, INC. filing history →

Source: SEC EDGAR

accession 0001193125-24-050739

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.